It's not always easy for a young company to build enough momentum to launch three commercial products in less than a decade of existence but that's exactly what Veracyte Inc. is on track to do by the end of this year. The molecular diagnostics company based in South San Francisco, Calif. just secured a financing agreement with Visium Healthcare Partners that provides up to $45 million through a term loan and securities purchase option.

A molecular testing company that has gained considerable traction over the past two years for its work in the concussion detection space has nearly doubled its total fundraising amount with a $46 million series D round. Lexington, Mass.-based Quanterix Corp. previously raised $54 million across its series A, B, and C rounds, and the D round brings the company's fundraising total to $100 million. Quanterix also noted that its post-money valuation now exceeds $200 million.

At first glance, three-year data supporting a commercialized technology already backed by a body of strong clinical evidence might not seem like a huge leap for the company selling the device. But for Endogastric Solutions Inc. (EGS), that's exactly what the company and — more importantly — payers have been waiting for.